Why Scopus BioPharma's Stock Is Surging Today

Scopus BioPharma SCPS shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.

Scopus BioPharma's stock has been rising Monday, up 102.07% to a price of $11.6. Monday the stock has been traded at a volume of 33.07 million, about 98379.56% of its recent 30-day volume average of 33.61 thousand.

The stock's 50-day moving average was $7.65 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $47.86 and fallen to a low of $5.13.

If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.